2 assets in Metastatic Carcinoma

Therapeutic assets addressing Metastatic Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer Metastatic Carcinoma	City of Hope Medical Center	P2	CCC (53)
Nedaplatin Metastatic Carcinoma	Zhejiang Cancer Hospital	P2	CCC (53)